Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Top Page
Altimmune
(NASDAQ:ALT)
45Neutral
Positive Factors
Clinical Development
Pemvidutide's potential to meet dual primary endpoints of MASH resolution and fibrosis improvement positions it as a leading candidate in its field.
Financial Position
Altimmune is well-capitalized with $132M in cash, providing financial runway into the second half of 2026.
Negative Factors
Market Competition
Competition is fierce in the obesity space, owing in large part to the success of the GLP-1 receptor drug class.
Altimmune (ALT) vs. S&P 500 (SPY)
Market Cap
$405.09M
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)―
Beta (1Y)2.32
Revenue Growth-95.31%
EPS Growth18.58%
CountryUS
Employees59
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.34
Shares Outstanding77,013,660
10 Day Avg. Volume3,074,372
30 Day Avg. Volume2,396,270
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20254.59
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.33Price Target Upside284.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Altimmune Business Overview & Revenue Model
Company DescriptionThe Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
How the Company Makes MoneyAltimmune generates revenue primarily through research and development collaborations, government contracts, and grants. The company partners with various organizations to develop and commercialize its product candidates. These partnerships often include milestone payments and royalties based on sales of successfully developed products. Additionally, Altimmune may receive funding from governmental and non-governmental agencies to support its R&D efforts in areas of public health interest.
Altimmune Financial Statement Overview
Summary
Altimmune faces significant challenges in achieving profitability and positive cash flow, reflected in negative margins and cash flow metrics. However, the company maintains a strong balance sheet with low leverage, providing a cushion for future growth opportunities.Income Statement
Altimmune has shown inconsistent revenue figures over the years, with a significant drop in the most recent period. Gross profit margins have been volatile, and the company has consistently posted negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges in achieving profitability.20
Very Negative
Balance Sheet
The company maintains a strong equity position with an equity ratio of 88.65% in the latest period, reflecting a solid balance sheet with minimal debt. The debt-to-equity ratio is favorable, indicating low financial leverage. However, the persistent net income losses have impacted the return on equity, which remains negative.70
Positive
Cash Flow
Altimmune has experienced negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, reflecting the company's difficulties in translating earnings into cash flow.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 20.00K | 426.00K | -68.00K | 4.41M | 8.19M | Gross Profit |
| 20.00K | -51.00K | -136.00K | 3.86M | -25.32M | EBIT |
| -103.17M | -95.93M | -87.74M | -96.91M | -54.80M | EBITDA |
| -94.81M | -87.94M | -84.40M | -96.53M | -54.15M | Net Income Common Stockholders |
| -95.06M | -88.45M | -84.71M | -96.17M | -49.04M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 131.89M | 197.81M | 184.88M | 190.30M | 215.92M | Total Assets |
| 139.31M | 210.64M | 206.93M | 218.86M | 245.12M | Total Debt |
| 1.68M | 671.00K | 1.12M | 1.54M | 1.82M | Net Debt |
| -35.24M | -134.45M | -109.97M | -188.77M | -114.09M | Total Liabilities |
| 15.80M | 16.54M | 21.64M | 19.73M | 19.24M | Stockholders Equity |
| 123.51M | 194.10M | 185.29M | 199.13M | 225.88M |
| Cash Flow | Free Cash Flow | |||
| -79.85M | -75.86M | -62.71M | -90.55M | -34.78M | Operating Cash Flow |
| -79.85M | -75.81M | -62.59M | -78.24M | -34.44M | Investing Cash Flow |
| -28.39M | 13.73M | -73.40M | 87.52M | -72.09M | Financing Cash Flow |
| 10.04M | 86.11M | 56.78M | 65.10M | 213.49M |
Altimmune Technical Analysis
Negative
5.55
Price Trends
6.58
Negative
7.26
Negative
6.99
Negative
Market Momentum
-0.35
Positive
38.47
Neutral
15.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Negative. The current price of 5.55 is below the 20-day moving average (MA) of 6.06, below the 50-day MA of 6.58, and below the 200-day MA of 6.99, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 38.47 is Neutral, neither overbought nor oversold. The STOCH value of 15.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALT.
Altimmune Risk Analysis
Altimmune disclosed 64 risk factors in its most recent earnings report. Altimmune reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Altimmune Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $105.32M | ― | -103.37% | ― | 303.27% | 36.35% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $1.58B | ― | 18.68% | ― | 36.00% | 63.50% | |
45 Neutral | $405.09M | ― | -59.86% | ― | -95.31% | 18.58% | |
39 Underperform | $1.27B | ― | 30.06% | ― | -30.65% | 77.62% | |
33 Underperform | $70.39M | ― | -106.64% | ― | -76.18% | 40.70% |
* Healthcare Sector Average
Performance Comparison
ALT
Altimmune
5.55
-4.47
-44.61%
BCRX
BioCryst
7.71
2.82
57.67%
INO
Inovio Pharmaceuticals
2.05
-8.76
-81.04%
NVAX
Novavax
8.10
3.12
62.65%
VXRT
Vaxart
0.55
-0.55
-50.00%
CYDY
CytoDyn
0.24
0.07
41.18%
Altimmune Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -6.57% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in Altimmune's pipeline with new INDs and a strong financial position. However, challenges such as increased expenses and a net loss, along with the retirement of a key executive, were noted.Highlights
Significant Progress in 2024
2024 was a year of significant progress for Altimmune, achieving milestones such as completing enrollment in the Phase 2b biopsy-based trial of pemvidutide in NASH. The company is on track for a top-line data readout in the second quarter of 2025.
New INDs and Phase 2 Trials
Altimmune submitted INDs for pemvidutide in two additional indications in Q4 2024, both cleared by the FDA. Phase 2 efficacy trials are set to start in mid-2025.
Strong Financial Position
Altimmune ended 2024 with $132 million in cash and investments, expected to fund operations well into the second half of 2026.
R&D Day Announcement
A virtual R&D Day is scheduled for March 13th, where additional indications and opportunities for pemvidutide will be disclosed.
No Safety Signals from FDA
The FDA identified no safety signals related to pemvidutide in over 500 subjects treated in prior studies.
Lowlights
Increased R&D Expenses
R&D expenses increased from $65.8 million in 2023 to $82.2 million in 2024, driven by costs related to pemvidutide development.
Net Loss for 2024
Altimmune reported a net loss of $95 million for 2024, compared to a net loss of $88 million in 2023.
Scott Harris Retirement Announcement
Scott Harris, the Chief Medical Officer, announced his retirement planned for early 2026, which may impact leadership continuity.
Company Guidance
During the Altimmune Fourth Quarter and Full Year 2024 Financial Results Conference Call, significant guidance was provided regarding the company's future plans and expected milestones. The company highlighted the completion of enrollment in the Phase 2b IMPACT trial for pemvidutide in NASH, with top-line data anticipated in Q2 2025. The trial's dual primary endpoints are NASH resolution and fibrosis improvement at 24 weeks. Altimmune plans to seek an end-of-Phase 2 meeting with the FDA in 2025, aiming to initiate a Phase 3 program in early 2026 if results are positive. The company also announced that two additional INDs for pemvidutide were cleared by the FDA, with Phase 2 trials expected to start in mid-2025. Financially, Altimmune reported total cash and investments of $132 million at the end of 2024, funding expected to support operations into the second half of 2026. R&D expenses for the year were $82.2 million, primarily driven by pemvidutide's development, while net loss totaled $95 million for 2024.Altimmune Corporate Events
Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Altimmune Reports 2024 Financial Results and R&D Progress
Positive
Feb 27, 2025
Altimmune announced its financial results for the fourth quarter and full year of 2024, highlighting significant progress in the development of pemvidutide. The company completed enrollment for the Phase 2b IMPACT trial in MASH and expects to report top-line data in Q2 2025. Additionally, Altimmune received FDA clearance for investigational new drug applications in two more indications, with Phase 2 trials slated for mid-2025. The company also strengthened its board with two new pharmaceutical industry veterans and plans to host a virtual R&D Day on March 13, 2025, to discuss further developments.
Executive/Board ChangesBusiness Operations and Strategy
Altimmune Expands Board Amid Late-Stage Drug Development
Positive
Feb 25, 2025
On February 24, 2025, Altimmune, Inc. expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, both seasoned executives in the biopharmaceutical industry. This strategic move comes as the company progresses into late-stage clinical development of pemvidutide, a promising treatment for liver and metabolic diseases. Lawver and Durso bring extensive experience in commercialization and corporate strategy, which is expected to bolster Altimmune’s efforts in transitioning to a pre-commercial-stage organization and advancing its strategic vision.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.